ALKBH5 and neoplasm: In the past few years, it has been revealed histone modifications and m6A RNA modifications synergistically contribute to drug resistance in tumor, particularly in the framework of acquired resistance, through a complex crosstalk mechanism.752 For instance, KDM4C orchestrates ALKBH5 expression through elevating the chromatin openness, suppressing H3K9me3 and facilitating recruitment of MYB and Pol II.